Kristina Jankovic/X
Apr 21, 2025, 10:45
Kristina Jankovic: DESTINY-Breast09 – Enhertu plus Pertuzumab Tops THP in 1L HER2+ metastatic breast cancer
Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared a post on X:
“DESTINY-Breast09: Enhertu plus pertuzumab shows superior PFS vs THP in 1L HER2+ mBC — first regimen in over a decade to outperform SoC.
Data to be presented at an upcoming medical meeting.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 05:01
Aug 7, 2025, 21:48
Aug 7, 2025, 21:02
Aug 7, 2025, 20:53